Suppressive immune microenvironment and CART therapy for glioblastoma: Future prospects and challenges DOI Creative Commons
Jie Lu,

Wen Huo,

Yingze Ma

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 600, P. 217185 - 217185

Published: Aug. 12, 2024

Glioblastoma, a highly malignant intracranial tumor, has acquired slow progress in treatment. Previous clinical trials involving targeted therapy and immune checkpoint inhibitors have shown no significant benefits treating glioblastoma. This ineffectiveness is largely due to the complex immunosuppressive environment of Glioblastoma cells exhibit low immunogenicity strong heterogeneity microenvironment replete with inhibitory cytokines, numerous cells, insufficient effective T cells. Fortunately, recent Phase I CART for glioblastoma confirmed its safety, small subset patients achieving survival benefits. However, continues face challenges, including blood-brain barrier obstruction, antigen loss, an tumor (TME). article provides detailed examination glioblastoma's microenvironment, both from intrinsic extrinsic cell factors, reviews current basic research on multi-targets treatment, concludes by outlining key challenges using therapy.

Language: Английский

Lung-Targeted Delivery of PTEN mRNA Combined with anti-PD-1-mediated Immunotherapy for In Situ Lung Cancer Treatment DOI

Yue Hu,

Xi He, Ping Chen

et al.

Acta Biomaterialia, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

1
Glioma lateralization: Focus on the anatomical localization and the distribution of molecular alterations (Review) DOI Creative Commons
Nilgün Tuncel Çini, Manuela Pennisi, Sıdıka Genç

et al.

Oncology Reports, Journal Year: 2024, Volume and Issue: 52(4)

Published: Aug. 16, 2024

It is well known how the precise localization of glioblastoma multiforme (GBM) predicts direction tumor spread in surrounding neuronal structures. The aim present review to reveal lateralization GBM by evaluating anatomical regions where it frequently located as main molecular alterations observed different brain regions. According literature, or most frequent has yet be determined. However, can said that more frontal lobe. Tractus and fascicles involved appear focused on corticospinal tract, superior longitudinal I, II III fascicles, arcuate fascicle long segment, strait inferior fronto‑occipital fasciculus. Considering features its involvement, logical are frontal‑temporal‑parietal‑occipital lobes, respectively. Although volumes higher right hemisphere, been determined prognosis patients diagnosed with cancer left hemisphere worse, probably reflecting distribution some detrimental such TP53 mutations, PTEN loss, EGFR amplification, MGMT promoter methylation. There theories stating less exposed external influences development responsible for functions necessary survival while tumors may aggressive. To shed light specific regions, article aimed at describing pathways gene mutations epigenetic modifications associated tumors.

Language: Английский

Citations

6
The STING Signaling: A Novel Target for Central Nervous System Diseases DOI Creative Commons
Min Song,

Jianxun Ren,

Zhipeng Zhu

et al.

Cellular and Molecular Neurobiology, Journal Year: 2025, Volume and Issue: 45(1)

Published: April 7, 2025

The canonical cyclic GMP-AMP (cGAMP) synthase (cGAS)-Stimulator of Interferon Genes (STING) pathway has been widely recognized as a crucial mediator inflammation in many diseases, including tumors, infections, and tissue damage. STING signaling can also be activated cGAS- or cGAMP-independent manner, although the specific mechanisms remain unclear. In-depth studies on structural molecular biology have led to development therapeutic strategies involving modulators their targeted delivery. These may effectively penetrate blood-brain barrier (BBB) target multiple central nervous system (CNS) diseases humans. In this review, we outline both non-canonical pathways activation describe general associations between activity CNS diseases. Finally, discuss prospects for delivery clinical application agonists inhibitors, highlighting novel

Language: Английский

Citations

0
Suppressive immune microenvironment and CART therapy for glioblastoma: Future prospects and challenges DOI Creative Commons
Jie Lu,

Wen Huo,

Yingze Ma

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 600, P. 217185 - 217185

Published: Aug. 12, 2024

Glioblastoma, a highly malignant intracranial tumor, has acquired slow progress in treatment. Previous clinical trials involving targeted therapy and immune checkpoint inhibitors have shown no significant benefits treating glioblastoma. This ineffectiveness is largely due to the complex immunosuppressive environment of Glioblastoma cells exhibit low immunogenicity strong heterogeneity microenvironment replete with inhibitory cytokines, numerous cells, insufficient effective T cells. Fortunately, recent Phase I CART for glioblastoma confirmed its safety, small subset patients achieving survival benefits. However, continues face challenges, including blood-brain barrier obstruction, antigen loss, an tumor (TME). article provides detailed examination glioblastoma's microenvironment, both from intrinsic extrinsic cell factors, reviews current basic research on multi-targets treatment, concludes by outlining key challenges using therapy.

Language: Английский

Citations

3